Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859383 | 1.00 | HIF1A (0.34) | HIF1APLK4CHEK1AURKACHUK | |
| SCHEMBL7861521 | 1.00 | HIF1A (0.34) | HIF1APLK4CHEK1AURKACHUK | |
| SCHEMBL1770152 | 0.85 | — | — | |
| SCHEMBL14611870 | 0.80 | ALDH1A1 (0.44) | — | |
| SCHEMBL7527116 | 0.79 | SPHK2 (0.44) | — | |
| SCHEMBL7863779 | 0.79 | SPHK2 (0.44) | — | |
| SCHEMBL7527117 | 0.79 | SPHK2 (0.44) | — | |
| SCHEMBL1770011 | 0.78 | — | — | |
| SCHEMBL7859358 | 0.72 | ALDH1A1 (0.46) | HIF1APLK4CHEK1AURKACHUK | |
| SCHEMBL17234569 | 0.72 | ALDH1A1 (0.46) | HIF1APLK4CHEK1AURKACHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1377642-A | Use of compound for preparing medicine for curing and preventing non-insulin dependent diabetes or obesity | BIOVITRUM AB (SE) | 2002-11-06 | — | — | CN | claimed |
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| CN-1377642-A | Use of compound for preparing medicine for curing and preventing non-insulin dependent diabetes or obesity | BIOVITRUM AB (SE) | 2002-11-06 | — | — | CN | disclosed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | HIF1A 1848/4885PLK4 2074/4885CHEK1 410/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | HIF1A 2228/4885PLK4 499/4885CHEK1 518/4885 |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | HIF1A 2228/4885PLK4 499/4885CHEK1 518/4885 |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | HIF1A 2228/4885PLK4 499/4885CHEK1 518/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | HIF1A 2228/4885PLK4 499/4885CHEK1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.